[go: up one dir, main page]

WO2006110367A3 - Methods and compositions for mycoplasma toxins - Google Patents

Methods and compositions for mycoplasma toxins Download PDF

Info

Publication number
WO2006110367A3
WO2006110367A3 PCT/US2006/012266 US2006012266W WO2006110367A3 WO 2006110367 A3 WO2006110367 A3 WO 2006110367A3 US 2006012266 W US2006012266 W US 2006012266W WO 2006110367 A3 WO2006110367 A3 WO 2006110367A3
Authority
WO
WIPO (PCT)
Prior art keywords
toxins
methods
mycoplasma
compositions
domains
Prior art date
Application number
PCT/US2006/012266
Other languages
French (fr)
Other versions
WO2006110367A2 (en
Inventor
Joel Barry Baseman
Thirumalai Rengasamy Kannan
Original Assignee
Univ Texas
Joel Barry Baseman
Thirumalai Rengasamy Kannan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Joel Barry Baseman, Thirumalai Rengasamy Kannan filed Critical Univ Texas
Priority to US11/887,995 priority Critical patent/US20090104185A1/en
Publication of WO2006110367A2 publication Critical patent/WO2006110367A2/en
Publication of WO2006110367A3 publication Critical patent/WO2006110367A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides Mycoplasma toxins, biologically active fragments/domains of the toxins, antibodies to the toxins, therapeutic fusion proteins comprising the toxins and/or biologically active fragments/domains of the toxins and nucleic acids encoding the toxins and fusion proteins. Also provided are methods of treating and/or preventing diseases and disorders using the compositions provided herein.
PCT/US2006/012266 2005-04-07 2006-03-31 Methods and compositions for mycoplasma toxins WO2006110367A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/887,995 US20090104185A1 (en) 2005-04-07 2006-03-31 Methods and Compositions for Mycoplasma Toxins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2005/011897 WO2006110132A1 (en) 2005-04-07 2005-04-07 Methods and compositions for mycoplasma pneumoniae exotoxins
USPCT/US2005/011897 2005-04-07

Publications (2)

Publication Number Publication Date
WO2006110367A2 WO2006110367A2 (en) 2006-10-19
WO2006110367A3 true WO2006110367A3 (en) 2006-12-21

Family

ID=37087319

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/011897 WO2006110132A1 (en) 2005-04-07 2005-04-07 Methods and compositions for mycoplasma pneumoniae exotoxins
PCT/US2006/012266 WO2006110367A2 (en) 2005-04-07 2006-03-31 Methods and compositions for mycoplasma toxins

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2005/011897 WO2006110132A1 (en) 2005-04-07 2005-04-07 Methods and compositions for mycoplasma pneumoniae exotoxins

Country Status (1)

Country Link
WO (2) WO2006110132A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115838691A (en) * 2022-10-08 2023-03-24 苏州大学附属儿童医院 Anti-human mycoplasma pneumoniae CARDS TX monoclonal antibody MM03H

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176331A1 (en) * 2001-02-12 2003-09-18 Rosenblum Michael G. Modified proteins, designer toxins, and methods of making thereof
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20060057155A1 (en) * 2001-03-30 2006-03-16 Vega Masignani Adp-ribosylating bacterial toxins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176331A1 (en) * 2001-02-12 2003-09-18 Rosenblum Michael G. Modified proteins, designer toxins, and methods of making thereof
US20060057155A1 (en) * 2001-03-30 2006-03-16 Vega Masignani Adp-ribosylating bacterial toxins
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARILE ET AL.: "Experimentally induced septic arthritis in chimpanzees infected with Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum", CLINICAL INFECTIOUS DISEASES, vol. 18, no. 5, 1994, pages 694 - 703 *
DANDEKAR ET AL.: "Re-annotating the Mycoplasma pneumoniae genome sequence: adding value, function and reading frames", NUCLEIC ACIDS RES., vol. 28, no. 7, 2000, pages 3278 - 3288 *
HOTT ET AL.: "Skeletal muscle-specific immunotoxin for the treatment of focal muscle spasm", NEUROLOGY, vol. 50, no. 2, 1998, pages 485 - 491 *
KANNAN AND BASEMAN: "ADP-ribosylating and vacuolating cytotoxin of My. pneumoniae represents unique virulence determinant among bacterial pathogens", PROC. NATL. ACAD. SCI., vol. 103, no. 17, 25 April 2006 (2006-04-25), pages 6724 - 6729 *
KANNAN ET AL.: "Identification and characterization of human surfactant protein A binding protein of M. pnseumoniae", INFECT. IMMUN., vol. 73, no. 5, May 2005 (2005-05-01), pages 2828 - 2834 *
PALLEN ET AL.: "An abundance of bacterial ADP-ribosyltransferase-implications for the origins of exotoxins", TRENDS IN MICROBIOLOGY, vol. 9, no. 7, July 2001 (2001-07-01), pages 302 - 307 *
SASAKI ET AL.: "The complete genomic sequence of Mycoplasma penetrans, an intracellular bacterial pathogen in humans", NUCLEIC ACIDS RES., vol. 30, no. 23, 2002, pages 5293 - 5300 *

Also Published As

Publication number Publication date
WO2006110132A1 (en) 2006-10-19
WO2006110367A2 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
WO2005063820A3 (en) Il-7 fusion proteins
WO2007091250A3 (en) Enzyme replacement therapy for treating lysosomal storage diseases
WO2005077042A3 (en) Albumin fusion proteins
TNSN08064A1 (en) Albumin fusion proteins
WO2008033413A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
WO2005003296A3 (en) Albumin fusion proteins
WO2007067730A3 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
AU2002305450A1 (en) Proteomimetic compounds and methods
DE60028970D1 (en) AT HER2 BINDING PEPTIDE COMPOUNDS
WO2007092640A3 (en) Antibodies that bind par-2
WO2004110472A3 (en) Fusion proteins
WO2007011693A3 (en) Compositions of placentally-derived stem cells for the treatment of cancer
WO2006087637A3 (en) Anti her2/neu antibody
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
WO2007064727A3 (en) Penetrabodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2005030793A3 (en) Antibodies which bind human cxcr3
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2006133457A3 (en) Bone morphogenetic variants, compositions and methods of treatment
ATE514718T1 (en) PEPTABODY FOR CANCER TREATMENT
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system
WO2007134118A3 (en) Protein based composition and methods of using same
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06749143

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11887995

Country of ref document: US